Experienced in Mast Cell Activation Syndrome (MCAS)

Dr. Michal G. Rose

Hematology Oncology
950 Campbell Ave, 
West Haven, CT 
Experienced in Mast Cell Activation Syndrome (MCAS)
950 Campbell Ave, 
West Haven, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Michal Rose is a Hematologist Oncology provider in West Haven, Connecticut. Dr. Rose is rated as an Experienced provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). Her top areas of expertise are Urticaria Pigmentosa, Chronic Myelogenous Leukemia (CML), Lung Cancer, and Systemic Mastocytosis.

Her clinical research consists of co-authoring 33 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of Mast Cell Activation Syndrome (MCAS).

Specialties
Hematology Oncology
Licenses
Internal Medicine in CT
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

950 Campbell Ave, West Haven, CT 06516

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

The National Myelodysplastic Syndromes Natural History Study
The National Myelodysplastic Syndromes Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: July 02, 2025
Intervention Type: Other
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Enrollment Status: Active_not_recruiting
Publish Date: March 30, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
A Phase II Study of RRx-001 in Platinum Refractory/Resistant Small Cell Carcinoma, EGFR TKI Resistant EGFR+ T790M Negative Non-Small Cell Lung Cancer, High Grade Neuroendocrine Tumors and Resistant/Refractory Ovarian Cancer Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: RRx-001, Cisplatin, Etoposide, Carboplatin, Irinotecan, Vinorelbine, Doxil, Gemcitabine, Taxane, Paclitaxel, Nab-Paclitaxel, Pemetrexed
Study Phase: Phase 2
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
A Randomized Phase II Study of Perioperative mFOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma
Enrollment Status: Completed
Publish Date: October 19, 2022
Intervention Type: Drug, Procedure
Study Drugs: Fluorouracil, Gemcitabine hydrochloride, Irinotecan hydrochloride, Oxaliplatin, Paclitaxel albumin-stabilized nanoparticle formulation
Study Phase: Phase 2
View 3 Less Clinical Trials

33 Total Publications

A mini review of leveraging biobanking in the identification of novel biomarkers in neurological disorders: insights from a rapid single-cell sequencing pipeline.
A mini review of leveraging biobanking in the identification of novel biomarkers in neurological disorders: insights from a rapid single-cell sequencing pipeline.
Journal: Frontiers in neuroscience
Published: July 31, 2024
Similar Doctors
Advanced in Mast Cell Activation Syndrome (MCAS)
Dr. John O. Mascarenhas
Hematology Oncology | Hematology
Advanced in Mast Cell Activation Syndrome (MCAS)
Dr. John O. Mascarenhas
Hematology Oncology | Hematology

Icahn School Of Medicine At Mount Sinai

1 Gustave L Levy Pl, 
New York, NY 
 (62.0 miles away)
212-731-7650
Languages Spoken:
English
See accepted insurances

John Mascarenhas is a Hematologist Oncology specialist and a Hematologist in New York, New York. Dr. Mascarenhas is rated as an Elite provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Myelofibrosis, Polycythemia Vera, Myeloproliferative Neoplasms (MPN), Bone Marrow Aspiration, and Splenectomy.

Advanced in Mast Cell Activation Syndrome (MCAS)
Dr. Joseph G. Jurcic
Hematology | Hematology Oncology | Oncology
Advanced in Mast Cell Activation Syndrome (MCAS)
Dr. Joseph G. Jurcic
Hematology | Hematology Oncology | Oncology

Trustees Of Columbia University In The City Of New York

161 Fort Washington Ave, 
New York, NY 
 (59.8 miles away)
212-305-3870
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Jurcic is a Hematologist and a Hematologist Oncology provider in New York, New York. Dr. Jurcic is rated as a Distinguished provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Acute Promyelocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Experienced in Mast Cell Activation Syndrome (MCAS)
Dr. Alec S. Goldenberg
Hematology Oncology | Hematology | Oncology
Experienced in Mast Cell Activation Syndrome (MCAS)
Dr. Alec S. Goldenberg
Hematology Oncology | Hematology | Oncology

North Shore Hematology Oncology Associates PC

48 Route 25a, 
Smithtown, NY 
 (31.8 miles away)
631-751-3000
Languages Spoken:
English
See accepted insurances

Alec Goldenberg is a Hematologist Oncology specialist and a Hematologist in Smithtown, New York. Dr. Goldenberg is rated as a Distinguished provider by MediFind in the treatment of Mast Cell Activation Syndrome (MCAS). His top areas of expertise are Blood Clots, Febrile Neutropenia, Hemochromatosis, and Non-Hodgkin Lymphoma.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rose's expertise for a condition
ConditionClose
      View All 11 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile